3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
8
Phase 1/2
6
Phase 2
5
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Cystadenocarcinoma, Serous
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Ameloblastoma
1
Interventions
Oxaliplatin
15
Fluorouracil
13
Bevacizumab
13
Leucovorin
10
Capecitabine
8
Folfox protocol
7
Irinotecan
6
IFL protocol
4
Cetuximab
4
Folic Acid
3
Aspirin
3
atezolizumab
2
XELOX
2
Surgical Procedures, Operative
2
Magnetic Resonance Spectroscopy
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
trifluridine tipiracil drug combination
1
trametinib
1
titanium silicide
1
sulindac sulfone
1
spartalizumab
1
sacituzumab govitecan
1
regorafenib
1
raltitrexed
1
pertuzumab
1
irinotecan sucrosofate
1
folfirinox
1
envafolimab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Colorectal Neoplasms
×
trametinib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled